Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial - Nitz, U; Gluz, O; Christgen, M (Breast Cancer Res Treat, 2017)